Last reviewed · How we verify
P-3058
P-3058 is a small molecule that targets the SGLT2 receptor.
P-3058 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | P-3058 |
|---|---|
| Sponsor | Polichem S.A. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, P-3058 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis (PHASE3)
- Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population (PHASE3)
- Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P-3058 CI brief — competitive landscape report
- P-3058 updates RSS · CI watch RSS
- Polichem S.A. portfolio CI